Compound Notes 5 min read
NAD+ vs NMN: A Critical Look at What the Industry Sells vs What the Research Supports
The longevity supplement industry has built itself around NAD+ precursors. The research behind those products is real but smaller in effect than the marketing implies. Here is the sharp version of the comparison, plus where the actual evidence sits.
Last reviewed: May 2026
The NAD+ category is the most-marketed corner of the longevity-supplement world. Walk through any wellness store, scroll any influencer feed, look at any “biological age” service, and you will hit NMN within the first scroll. The marketing is loud. The research, when you look at it carefully, is more modest.
This is the critical version of the comparison. The science behind NAD+ supplementation is real. The application of that science to consumer products is patchy. A serious researcher looking at the NAD precursor category should leave with both a working understanding of the molecule and a healthy skepticism toward most of the products selling it.
The molecule, briefly
NAD+ (nicotinamide adenine dinucleotide) is a cofactor every cell in your body needs to run metabolism. It is the substrate for the SIRT1-7 sirtuin enzymes that David Sinclair’s lab and others have linked to longevity signalling. NAD+ levels decline with age in most tissues studied, with the consensus figure landing somewhere around a 20 to 50% drop between young adulthood and the seventh decade.
That decline is the foundation of the case for NAD+ precursor supplementation. If less NAD+ is the problem, more NAD+ might be the solution. The case is biologically reasonable. The execution is where the industry has overshot.
NAD+ vs NMN vs NR
NAD+ itself is a large molecule. Direct oral NAD+ supplementation has poor bioavailability because the molecule does not survive digestion intact. The precursor approach is the workaround: smaller molecules that the body converts to NAD+ once absorbed.
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two precursor forms with the strongest research base. Both raise plasma NAD+ levels in human trials. The marketing pitch for NMN is typically that it is “one step closer” to NAD+ in the biosynthetic pathway than NR, which sounds like an advantage and is mostly a marketing point. The actual delivery problem is whether the precursor crosses cell membranes and reaches mitochondria, which is where NAD+ matters for energy production.
The honest comparison: NR has a longer human-trial track record. NMN has more recent data and a heavier marketing push. The difference in clinical effect between them, where head-to-head data exists, is small. Anyone selling either as obviously superior is overclaiming.
Where the marketing overshoots
Three claims to be skeptical of:
“NMN reverses biological age.” The published data shows modest biomarker shifts. Plasma NAD+ rises. Some inflammatory markers move favourably in some studies. The leap from those biomarker shifts to “biological age reversal” is several layers ahead of what the data supports. The horizon-of-reasonable-claim is closer to “modestly supports one specific axis of cellular aging.”
“500 mg of NMN is the research dose.” Many of the human studies that produced the favourable biomarker results used doses in this range, but not all. Bioavailability of oral NMN varies between products in ways that the supplement-industry quality control has not consistently addressed. A 500 mg dose from a low-quality product may deliver less effective compound than a 250 mg dose from a higher-quality product.
“NMN works better than diet and exercise.” Nothing in the published literature supports this. Aerobic exercise raises NAD+ levels in muscle tissue more reliably than oral supplementation in most studies, and the magnitude of the exercise effect is larger. Diet and sleep also influence NAD+ levels through pathways the supplement does not address. Treating NMN as a substitute for the lifestyle inputs that move NAD+ is the wrong frame.
What the research actually supports
NAD+ precursor supplementation, taken consistently at research-supported doses (250 to 1000 mg daily depending on the precursor) from a quality-controlled source, produces measurable increases in plasma NAD+ levels. This is the strongest claim the literature unambiguously supports.
From there, the picture gets thinner. Some studies show favourable biomarker shifts (insulin sensitivity, inflammatory markers, exercise capacity). Others show no detectable changes in healthy adults. Effect sizes, where they exist, are modest. The compounds are genuinely worth including in a longevity-context protocol with realistic expectations. They are not the hero of any reasonable protocol.
Where injectable NAD+ fits
Direct injection of NAD+ bypasses the precursor question entirely. The bioavailability advantage is real. The trade-off is that injectable NAD+ requires research-context dosing protocols, the compound is research-grade only, and the operational complexity is higher than oral supplementation. Our NAD+ vial is catalogued for this protocol pattern, with the standard research-context posture.
For researchers who want the cofactor pathway support without the injectable side, oral NMN or NR from a quality source remains a reasonable choice. The effect is smaller than the marketing implies but real.
The supplement-industry quality problem
The NMN supplement category has inconsistent quality control at the consumer level. Independent testing has repeatedly found products that contain less than the labelled dose, products that contain degraded NMN (the compound is mildly thermally unstable), and products with manufacturing impurities. The rule of thumb: if a product does not have third-party Certificate of Analysis available on request, the labelled dose is not the dose you are taking.
This is a place where the supply-chain side matters more than the molecule side. A 500 mg labelled NMN product that delivers 200 mg of intact compound is worse than a 250 mg labelled product that delivers what it says.
The honest takeaway
NAD+ precursor supplementation is reasonable to include in a longevity-context protocol. The mechanism is real. The effect size is modest. The supplement-industry version of the story is louder than the data supports. Treat NMN/NR as one input among several, paired with the lifestyle inputs that actually move the NAD+ curve more (exercise, sleep, weight management).
For research-context injectable NAD+ protocols, the same realism applies. The compound is biologically interesting. The protocol is operationally heavier than oral. The pairing with the supplement layer (electrolyte support, sleep architecture support) often matters more than the dose of the precursor itself.